Results of the INSEMA trial indicated that it’s safe to omit axillary sentinel lymph node biopsy in patients with clinically ...
“There are lots of reasons to stop drinking sugar-sweetened beverages. One of them is because they increase your risk of ...
AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...
“Whole grains, fibre and dairy products have the strongest evidence for preventing bowel cancer. Data suggests that eating ...
The survival rate for children with a rare but deadly cancer could one day be improved by adding an existing drug—which is ...
On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San ...
Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...
The number of people diagnosed with brain tumours in Scotland has risen by 30% in the last two decades, according to new ...
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...